Dabigatran requires dose reduction in elderly patients primarily because it is eliminated differently from other novel oral anticoagulants. The reason is:

• A Dabigatran is extensively metabolized by CYP3A4, which decreases with age
• B Dabigatran undergoes age-dependent changes in plasma protein binding
• C Dabigatran is 80% renally eliminated unchanged, and GFR declines with age ✓
• D Dabigatran's volume of distribution increases with age due to increased adipose tissue

Explanation

Dabigatran etexilate is a prodrug hydrolyzed to dabigatran (active form) by esterases in the gut and liver. Importantly, 80% of active dabigatran is excreted unchanged by the kidneys. Since GFR naturally declines with age (estimated 1 mL/min/year after age 40), elderly patients accumulate dabigatran, increasing bleeding risk. Rivaroxaban, apixaban, and edoxaban are predominantly hepatically metabolized, making them relatively safer in mild-moderate renal impairment.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.